Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS) Teachey DT; Seif AE; Grupp SABr J Haematol 2010[Jan]; 148 (2): 205-16Autoimmune lymphoproliferative syndrome (ALPS) is a disorder of T cell dysregulation caused by defective Fas-mediated apoptosis. Patients with ALPS can develop a myriad of clinical manifestations including lymphadenopathy, hepatosplenomegaly, autoimmunity and increased rates of malignancy. ALPS may be more common that originally thought, and testing for ALPS should be considered in patients with unexplained lymphadenopathy, hepatosplenomegaly, and/or autoimmunity. As the pathophysiology of ALPS is better characterized, a number of targeted therapies are in preclinical development and clinical trials with promising early results. This review describes the clinical and laboratory manifestations found in ALPS patients, as well as the molecular basis for the disease and new advances in treatment.|Anemia, Hemolytic, Autoimmune/diagnosis[MESH]|Autoimmune Lymphoproliferative Syndrome/*diagnosis/drug therapy/genetics[MESH]|Diagnosis, Differential[MESH]|Glucocorticoids/therapeutic use[MESH]|Humans[MESH]|Immunologic Factors/therapeutic use[MESH]|Immunosuppressive Agents/therapeutic use[MESH]|Mutation[MESH]|Neutropenia/diagnosis[MESH]|Purpura, Thrombocytopenic/diagnosis[MESH] |